Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Assets: 2016-2025

Historic Non-Current Assets for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $547.2 million.

  • Ultragenyx Pharmaceutical's Non-Current Assets fell 25.92% to $547.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $547.2 million, marking a year-over-year decrease of 25.92%. This contributed to the annual value of $686.3 million for FY2024, which is 9.55% down from last year.
  • Ultragenyx Pharmaceutical's Non-Current Assets amounted to $547.2 million in Q3 2025, which was down 6.69% from $586.5 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Non-Current Assets high stood at $758.8 million for Q4 2023, and its period low was $526.8 million during Q1 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $639.0 million (2023), whereas its average is $651.0 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Non-Current Assets spiked by 60.93% in 2021 and then declined by 25.92% in 2025.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Non-Current Assets stood at $665.8 million in 2021, then declined by 0.64% to $661.5 million in 2022, then grew by 14.71% to $758.8 million in 2023, then fell by 9.55% to $686.3 million in 2024, then dropped by 25.92% to $547.2 million in 2025.
  • Its Non-Current Assets stands at $547.2 million for Q3 2025, versus $586.5 million for Q2 2025 and $612.8 million for Q1 2025.